A broader question might be to what extent are companies being forced by the unreasonable demands of this 'clunky' system to make this kind of proposal. Isn't the proposal a response to something? MSAC would be wise to consider what that something is rather than issue statements shifting blame and insulting healthcare companies.
Where does the system end if statements like this become a feature of our decision-making?
July 8, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech -
Pharmac scraps plan to remove low-ranked medicines from options for funding list
December 18, 2025 - - Latest News -
PBAC reflects on a year shaped by major reviews and rising workload
December 18, 2025 - - Latest News -
Priceline moves to stabilise banner group as pressures force administrators
December 17, 2025 - - Latest News -
Rare Cancers Australia gearing up for 2026 Kosi Challenge with Pharma Cup up for grabs again
December 17, 2025 - - Latest News

